These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21512416)

  • 1. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.
    Wu JY; Shih JY; Chen KY; Yang CH; Yu CJ; Yang PC
    Medicine (Baltimore); 2011 May; 90(3):159-167. PubMed ID: 21512416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
    Gazdar AF
    Medicine (Baltimore); 2011 May; 90(3):168-170. PubMed ID: 21512415
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
    Sasaki H; Endo K; Okuda K; Kawano O; Kitahara N; Tanaka H; Matsumura A; Iuchi K; Takada M; Kawahara M; Kawaguchi T; Yukiue H; Yokoyama T; Yano M; Fujii Y
    J Cancer Res Clin Oncol; 2008 May; 134(5):569-77. PubMed ID: 17932690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
    Hotta K; Kiura K; Toyooka S; Takigawa N; Soh J; Fujiwara Y; Tabata M; Date H; Tanimoto M
    J Thorac Oncol; 2007 Jul; 2(7):632-7. PubMed ID: 17607119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.
    Tateishi K; Ichiyama T; Hirai K; Agatsuma T; Koyama S; Hachiya T; Morozumi N; Shiina T; Koizumi T
    Med Oncol; 2013 Mar; 30(1):450. PubMed ID: 23315220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
    Shukuya T; Takahashi T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Takahashi K; Yamamoto N
    Cancer Sci; 2011 May; 102(5):1032-7. PubMed ID: 21272159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
    Asahina H; Yamazaki K; Kinoshita I; Sukoh N; Harada M; Yokouchi H; Ishida T; Ogura S; Kojima T; Okamoto Y; Fujita Y; Dosaka-Akita H; Isobe H; Nishimura M
    Br J Cancer; 2006 Oct; 95(8):998-1004. PubMed ID: 17047648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
    N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
    Kimura H; Kasahara K; Shibata K; Sone T; Yoshimoto A; Kita T; Ichikawa Y; Waseda Y; Watanabe K; Shiarasaki H; Ishiura Y; Mizuguchi M; Nakatsumi Y; Kashii T; Kobayashi M; Kunitoh H; Tamura T; Nishio K; Fujimura M; Nakao S
    J Thorac Oncol; 2006 Mar; 1(3):260-7. PubMed ID: 17409866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
    Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
    Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
    Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
    Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
    Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
    Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
    Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
    Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
    Hirose T; Fujita K; Kusumoto S; Oki Y; Murata Y; Sugiyama T; Ishida H; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ohmori T; Sasaki Y
    Lung Cancer; 2016 Mar; 93():69-76. PubMed ID: 26898617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.